Dr Paul Clewlow
Paul joined Sygnature in April 2009 as a member of the Board of Directors.
He has over 26 years of scientific and business development experience gained in the oil and pharmaceutical industries. Paul was previously Senior VP, Business Development, at Argenta Discovery and Business Development Director at Pharmaceutical Profiles (now Quotient Clinical). He also held senior business development positions at Medeval (now ICON Clinical), was Business Development Manager at Salford Ultrafine Chemicals (now SAFC Pharma), and had several research and technical sales positions at Exxon Chemical (now ExxonMobil Chemical). Paul has a BSc (Hons.) in chemistry from the University of Leicester, a PhD in synthetic organic chemistry from the University of Wales, and undertook post-doctoral research at Arizona State University, and at the ETH Zürich.